Weight loss and resting energy expenditure in patients with chronic hepatitis C before and during standard treatment

Fioravante, Milena; Alegre, Sarah Monte; Marin, Daniela Miguel; Lorena, Sônia Letícia Silva; Pereira, Tiago; Soares, Elza Cotrim

doi:10.1016/j.nut.2011.08.010

Cited by 19 publications

(19 citation statements)

References 20 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Therefore, before starting antiviral therapy, it is better to improve some metabolic disorders including obesity and insulin resistance by diet therapy and exercise therapy. After starting IFN-based therapy, body weight decreases due to decreased appetite and some digestive symptoms in many patients [28, 29]. A recent study showed that resting energy expenditure did not increase during IFN-based antiviral therapy, and weight loss during the therapy was ascribed to a decrease in energy intake [29].…”

Section: Nutrition Therapy For Chc Patientsmentioning

confidence: 99%

“…After starting IFN-based therapy, body weight decreases due to decreased appetite and some digestive symptoms in many patients [28, 29]. A recent study showed that resting energy expenditure did not increase during IFN-based antiviral therapy, and weight loss during the therapy was ascribed to a decrease in energy intake [29]. Although there are no guidelines on how nutrition therapy should be conducted, a decrease in quality of life or malnutrition must be prevented for avoiding an interruption in antiviral therapy.…”

Section: Nutrition Therapy For Chc Patientsmentioning

confidence: 99%

See 1 more Smart Citation

Nutrition Therapy for Liver Diseases Based on the Status of Nutritional Intake

Yasutake

Kohjima

Nakashima

et al. 2012

Gastroenterology Research and Practice

View full text Add to dashboard Cite

The dietary intake of patients with nonalcoholic fatty liver disease (NAFLD) is generally characterized by high levels of carbohydrate, fat, and/or cholesterol, and these dietary patterns influence hepatic lipid metabolism in the patients. Therefore, careful investigation of dietary habits could lead to better nutrition therapy in NAFLD patients. The main treatment for chronic hepatitis C (CHC) is interferon-based antiviral therapy, which often causes a decrease in appetite and energy intake; hence, nutritional support is also required during therapy to prevent undernourishment, treatment interruption, and a reduction in quality of life. Moreover, addition of some nutrients that act to suppress viral proliferation is recommended. As a substitutive treatment, low-iron diet therapy, which is relatively safe and effective for preventing hepatocellular carcinoma, is also recommended for CHC patients. Some patients with liver cirrhosis (LC) have decreased dietary energy and protein intake, while the number of LC patients with overeating and obesity is increasing, indicating that the nutritional state of LC patients has a broad spectrum. Therefore, nutrition therapy for LC patients should be planned on an assessment of their complications, nutritional state, and dietary intake. Late evening snacks, branched-chain amino acids, zinc, and probiotics are considered for effective nutritional utilization.

show abstract

Section: Nutrition Therapy For Chc Patientsmentioning

confidence: 99%

Section: Nutrition Therapy For Chc Patientsmentioning

confidence: 99%

Nutrition Therapy for Liver Diseases Based on the Status of Nutritional Intake

Yasutake

Kohjima

Nakashima

et al. 2012

Gastroenterology Research and Practice

View full text Add to dashboard Cite

show abstract

“…According to medical reports, in addition to the therapeutic objective, side effects are often associated with standard therapy. Some of these side effects include depression, anxiety, psychosis, cognitive impairment and body weight (BW) loss [3][4][5][6]. The exact contributions of each component of combined therapy to the side effects have not been elucidated, but there is a view that they are mainly related to interferon alpha [7][8][9][10].…”

Section: Introductionmentioning

confidence: 99%

Psychomotor activity and body weight gain after exposure to low ribavirin doses in rats: role of treatment duration

Petković

Stojadinović

Kesić

et al. 2019

ARCH BIOL SCI BELGRA

View full text Add to dashboard Cite

Clinically-related basic studies on the behavioral effects of ribavirin treatment are still lacking despite its wide use as an antiviral medication. This paper considers the effects of low ribavirin doses (10, 20 and 30 mg/kg/day) on psychomotor activity (novelty-induced exploratory behavior, d-amphetamine (AMPH, 1.5 mg/kg, intraperitoneal)-induced motor activity), and body weight gain in socially undisturbed adult male Wistar rats 24 h after the first, seventh and fourteenth once-a-day injection. Low doses of ribavirin were tested in an attempt to avoid the recognized systemic side effects related to high-dose usage. None of the singly applied ribavirin doses affected exploratory/spontaneous and AMPH-induced motor behavior (locomotion, stereotypy-like and vertical activity), however, body weight gain was significantly lower after treatment with 30 mg/kg of ribavirin. The 7-and 14-day treatments with 10 and 30 mg/kg/day of ribavirin significantly suppressed novelty-induced locomotion and body weight gain; the 14-day treatment with ribavirin at a dose of 30 mg/kg/ day decreased AMPH-induced stereotypy. These findings indicate that repeated application (up to 14 days) of low ribavirin doses results in low novelty-induced locomotion along with reduced weight gain, accentuating the existence of a U-shaped dose-response relationship with a prolonged duration of ribavirin treatment.

show abstract

“…Fioravante et al demonstrated that the weight loss during treatment was accompanied by a significant decrease in energy intake as assessed by 24-h recall. However, there was no change in resting energy expenditure19.…”

Section: Discussionmentioning

confidence: 87%

Spontaneous Weight Change during Chronic Hepatitis C Treatment: Association with Virologic Response Rates

Alwakeel¹,

Zaghla²,

Omar³

et al. 2013

Int. J. Med. Sci.

View full text Add to dashboard Cite

Objective: We examined weight changes during chronic hepatitis C (CHC) therapy and association with virologic response.Methods: Weight changes were compared between subjects achieving rapid, early, and sustained virologic response rates (RVR, EVR, and SVR). RVR, EVR and SVR were compared among patients with or without weight loss of ≥ 0.5 body mass index (BMI) units (kg/m2) at 4, 12, 48 weeks.Results: CHC therapy was initiated in 184 cases. Median pretreatment BMI was 27.7 (18.4-51.3) with 38% overweight and 31% obese (BMI ≥25 and ≥ 30, respectively). Among patients with liver biopsies (n = 90), steatosis was present in 31.6%; fibrosis grade of 1-2/6 in 46%, 3-4 in 37.3% and 5-6 in 14.7%. Mean weight loss at 4, 12, 24 and 48 weeks of therapy were 1.2, 2.6, 3.8 and 3.3 kg, respectively. After 4 and 12 weeks of treatment, 38% and 54.3% had a BMI decrement of ≥ 0.5 kg/m2. For genotype 1, weight loss at 4 weeks was associated with significantly higher EVR (90.0% vs. 70%, p = 0.01) and a tendency towards better RVR and SVR (42.9% vs. 26.0% and 55.2% vs. 34.8%, respectively, p = 0.08). In multivariate analysis, weight loss at 4 weeks was independently associated with EVR (OR 6.3, p = 0.02) but was not significantly associated with RVR or SVRConclusions: Spontaneous weight loss at 4 and 12 weeks of CHC therapy was associated with improved EVR. Weight loss at 4 weeks was an independent predictor of EVR but not SVR.

show abstract

Weight loss and resting energy expenditure in patients with chronic hepatitis C before and during standard treatment

Cited by 19 publications

References 20 publications

Nutrition Therapy for Liver Diseases Based on the Status of Nutritional Intake

Nutrition Therapy for Liver Diseases Based on the Status of Nutritional Intake

Psychomotor activity and body weight gain after exposure to low ribavirin doses in rats: role of treatment duration

Spontaneous Weight Change during Chronic Hepatitis C Treatment: Association with Virologic Response Rates

Contact Info

Product

Resources

About